2019
Medical and Surgical Management of Empyema
Godfrey M, Bramley K, Detterbeck F. Medical and Surgical Management of Empyema. Seminars In Respiratory And Critical Care Medicine 2019, 40: 361-374. PMID: 31525811, DOI: 10.1055/s-0039-1694699.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsVideo-assisted thoracic surgeryChest tube drainageCommon clinical problemIntrapleural fibrinolyticsSurgical decorticationMost patientsTube drainageClinical courseSurgical managementTherapeutic optionsThoracic surgeryPresent cliniciansPleural spaceClinical problemDisease processEarly interventionCulture resultsEarly drainagePhysiologic impactEmpyemaMultidisciplinary collaborationClear benefitCliniciansAntibioticsIntervention
2018
Identifying Drivers of Multiple Readmissions After Pulmonary Lobectomy
Jean RA, Chiu AS, Hoag JR, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Identifying Drivers of Multiple Readmissions After Pulmonary Lobectomy. The Annals Of Thoracic Surgery 2018, 107: 947-953. PMID: 30336117, DOI: 10.1016/j.athoracsur.2018.08.070.Peer-Reviewed Original ResearchConceptsPulmonary lobectomyMultiple readmissionsSecond readmissionFirst readmissionIndex hospitalizationPostoperative infectionLung cancerPrimary diagnosisHeart diseaseClinical Classification Software codesNationwide Readmissions DatabaseTime of readmissionPostoperative arrhythmiasPostoperative complicationsPostoperative sepsisPerioperative periodPostoperative periodClinical factorsReadmissionLobectomyPatientsStudy periodImportant markerDiagnosisHealthcare qualityTiming and Risk Factors Associated With Venous Thromboembolism After Lung Cancer Resection
Thomas DC, Arnold BN, Hoag JR, Salazar MC, Detterbeck FC, Boffa DJ, Kim AW, Blasberg JD. Timing and Risk Factors Associated With Venous Thromboembolism After Lung Cancer Resection. The Annals Of Thoracic Surgery 2018, 105: 1469-1475. PMID: 29501644, DOI: 10.1016/j.athoracsur.2018.01.072.Peer-Reviewed Original ResearchConceptsPostdischarge venous thromboembolismVenous thromboembolismHospital dischargeOperative timeRisk factorsPostdischarge prophylaxisVTE eventsMultivariable analysisLung cancerNational Surgical Quality Improvement Program databaseQuality Improvement Program databaseExtended VTE prophylaxisLung cancer resectionImprovement Program databaseShorter operative timeLengthy resectionsVTE prophylaxisAnatomic resectionClinical characteristicsInvasive resectionLung resectionOlder patientsOpen resectionCancer resectionIndependent predictors
2017
Length of Stay From the Hospital Perspective
Rosen JE, Salazar MC, Dharmarajan K, Kim AW, Detterbeck FC, Boffa DJ. Length of Stay From the Hospital Perspective. Annals Of Surgery 2017, 266: 383-388. PMID: 27564681, DOI: 10.1097/sla.0000000000001971.Peer-Reviewed Original ResearchConceptsMedian LOSLength of stayEarly discharge practicesDischarge practicesReadmission ratesEarly dischargeCancer-accredited hospitalsNational Cancer DatabaseLung cancer surgeryRisk of readmissionHospital discharge practicesHierarchical logistic regression modelsLack of effectLogistic regression modelsMore readmissionsUnplanned readmissionThoracotomy approachCancer surgeryReadmission riskLung cancerCancer DatabaseInclusion criteriaReadmissionHospital perspectivePatients
2016
Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer
Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2016, 12: 314-322. PMID: 27720827, DOI: 10.1016/j.jtho.2016.09.122.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPneumonectomyPrognosisRetrospective StudiesSurvival RateTime FactorsConceptsNational Cancer Data BaseNeoadjuvant chemoradiationTiming of surgeryOverall survivalAdvanced non-small cell lung cancerNon-small cell lung cancerStage IIIA-N2 NSCLCStage IIIA NSCLCKaplan-Meier methodOverall survival rateSubset of patientsCell lung cancerLog-rank testMultivariate survival analysisProportional hazards modelIIIA NSCLCN2 NSCLCNeoadjuvant therapyTrimodality therapySurgical resectionClinical stageRetrospective studyLung cancerHazards modelSurvival rateEstimating the Annual Incremental Cost of Several Complications Following Pulmonary Lobectomy
Jawitz OK, Boffa DJ, Detterbeck FC, Wang Z, Kim AW. Estimating the Annual Incremental Cost of Several Complications Following Pulmonary Lobectomy. Seminars In Thoracic And Cardiovascular Surgery 2016, 28: 531-540. PMID: 28043473, DOI: 10.1053/j.semtcvs.2016.06.001.Peer-Reviewed Original ResearchConceptsAcute respiratory failureLength of hospitalizationPulmonary lobectomyHospital stayRespiratory failureMajor complicationsAir leakAnnual health care expendituresRetrospective cohort analysisNational Inpatient SampleLength of stayPostoperative air leaksUtilization Project databaseAnnual incremental costMultivariable quantile regression modelsAggregate national costHealth care expendituresHealth care qualityLarge national datasetCommon complicationVATS lobectomyCostly complicationInpatient SampleHospital costsClinical data
2015
Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database
Leuzzi G, Rocco G, Ruffini E, Sperduti I, Detterbeck F, Weder W, Venuta F, Van Raemdonck D, Thomas P, Facciolo F, Group E. Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database. Journal Of Thoracic And Cardiovascular Surgery 2015, 151: 47-57.e1. PMID: 26403869, DOI: 10.1016/j.jtcvs.2015.08.034.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAsiaChemotherapy, AdjuvantChi-Square DistributionChildDatabases, FactualDisease ProgressionDisease-Free SurvivalEuropeFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNorth AmericaPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentRisk FactorsSocieties, MedicalThymectomyThymomaThymus NeoplasmsTime FactorsTreatment OutcomeTumor BurdenYoung AdultConceptsRelapse-free survivalAdvanced thymomaMultimodality therapyOverall survivalT classificationPropensity score-matched cohort studyMultivariate Cox proportional hazards modelPropensity score-matched analysisCox proportional hazards modelPathologic T classificationStage III thymomaThoracic Surgeons databaseSignificant survival advantageSpecific pathologic featuresStrong predictive factorProportional hazards modelInduction therapyAdjuvant therapyPT3 tumorsCohort studyIndependent predictorsPrognostic impactMultivariable analysisPathologic featuresPredictive factors
2014
Hospital Readmission After Pulmonary Lobectomy Is Not Affected by Surgical Approach
Assi R, Wong DJ, Boffa DJ, Detterbeck FC, Wang Z, Chupp GL, Kim AW. Hospital Readmission After Pulmonary Lobectomy Is Not Affected by Surgical Approach. The Annals Of Thoracic Surgery 2014, 99: 393-398. PMID: 25497070, DOI: 10.1016/j.athoracsur.2014.10.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansMaleMiddle AgedPatient ReadmissionPneumonectomyRetrospective StudiesTime FactorsConceptsCharlson Comorbidity IndexDays of dischargePredictors of readmissionIntensive care unitUnplanned returnPulmonary lobectomyComorbidity indexHospital readmissionSurgical approachCare unitHigher Charlson comorbidity indexMedian hospital lengthMultivariate logistic regression methodThoracic surgery serviceHigh-risk patientsPostoperative mortalityPostoperative transferHospital lengthPostoperative complicationsExpiratory volumeSurgery serviceOpen thoracotomyPathologic diagnosisUnplanned transfersMedical recordsNow or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database
Boffa DJ, Hancock JG, Yao X, Goldberg S, Rosen JE, Kim AW, Moreno A, Detterbeck FC. Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 99: 200-208. PMID: 25440272, DOI: 10.1016/j.athoracsur.2014.08.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseStage III non-small cell lung cancerPreoperative chemotherapyPostoperative chemotherapyLung cancerCancer DatabaseIII-N2 non-small cell lung cancerStage III lung cancerStage III NSCLC patientsTiming of chemotherapyCell lung cancerCox proportional hazardsSeparate Cox modelsNSCLC patientsChemotherapy resultsChemotherapy timingAdjusted comparisonsChemotherapy approachesChemotherapyCox modelProportional hazardsPatientsTumor attributesCStagePredictors of Mortality After Surgical Management of Lung Cancer in the National Cancer Database
Rosen JE, Hancock JG, Kim AW, Detterbeck FC, Boffa DJ. Predictors of Mortality After Surgical Management of Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 98: 1953-1960. PMID: 25443003, DOI: 10.1016/j.athoracsur.2014.07.007.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseLobectomy/bilobectomyAdverse eventsSurgical resectionMultivariable analysisMale sexFacility volumeLung cancerCancer DatabaseLung cancer surgeryPredictors of mortalityRight-sided tumorsDay of surgeryCell lung cancerStandard of careExtended lengthLarge cancer registryPerioperative outcomesPrimary endpointNSCLC patientsSurgical complicationsWedge resectionSurgical treatmentCancer RegistryThymic carcinoma outcomes and prognosis: Results of an international analysis
Ahmad U, Yao X, Detterbeck F, Huang J, Antonicelli A, Filosso PL, Ruffini E, Travis W, Jones DR, Zhan Y, Lucchi M, Rimner A. Thymic carcinoma outcomes and prognosis: Results of an international analysis. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 95-101.e2. PMID: 25524678, DOI: 10.1016/j.jtcvs.2014.09.124.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingPractice Patterns, Physicians'Proportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSex FactorsThymectomyThymomaThyroid NeoplasmsTime FactorsTreatment OutcomeConceptsRecurrence-free survivalEarly Masaoka stageR0 resectionOverall survivalRadiation therapyMasaoka stageThymic carcinomaMale genderLonger recurrence-free survivalMedian overall survivalStage IV diseaseAdjuvant radiation therapyMasaoka stage IPreoperative radiation therapyPrimary outcome measureSquamous cell carcinomaPredominant histologic subtypeAdjuvant chemotherapyImproved OSInduction chemotherapyProlonged OSCumulative incidenceHistologic subtypeMultivariable analysisTreatment patternsOutcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases
Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, Guerrera F, Detterbeck F, Committee E. Outcome of primary neuroendocrine tumors of the thymus: A joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 103-109.e2. PMID: 25308116, DOI: 10.1016/j.jtcvs.2014.08.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChemotherapy, AdjuvantDatabases, FactualFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingNeuroendocrine TumorsProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsThymectomyThymus NeoplasmsTime FactorsTreatment OutcomeYoung AdultConceptsInternational Thymic Malignancy Interest GroupMasaoka-Koga stageOverall survivalCompleteness of resectionPrimary neuroendocrine tumorThoracic Surgeons databasePrognostic factorsHistologic subtypeSurgeons databaseNeuroendocrine tumorsHigher biologic aggressivenessMasaoka-Koga stage ICommon histologic subtypeMedian overall survivalEuropean SocietyRetrospective multicenter studyKaplan-Meier methodStrong prognostic factorLog-rank testInduction therapyAdjuvant treatmentCumulative incidenceResection statusComplete resectionMulticenter studyFewer complications result from a video-assisted approach to anatomic resection of clinical stage I lung cancer
Boffa DJ, Dhamija A, Kosinski AS, Kim AW, Detterbeck FC, Mitchell JD, Onaitis MW, Paul S. Fewer complications result from a video-assisted approach to anatomic resection of clinical stage I lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2014, 148: 637-643. PMID: 24529729, DOI: 10.1016/j.jtcvs.2013.12.045.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overFemaleHumansLogistic ModelsLung NeoplasmsMaleMiddle AgedMultivariate AnalysisNeoplasm StagingOdds RatioPneumonectomyPostoperative ComplicationsPropensity ScoreRisk FactorsThoracic Surgery, Video-AssistedThoracotomyTime FactorsTreatment OutcomeYoung AdultConceptsStage I lung cancerClinical stage I lung cancerI lung cancerThoracic Surgeons databaseAnatomic resectionLung cancerSurgeons databaseStage I primary lung cancerVideo-assisted thoracic surgery approachEarly-stage lung cancerMore pulmonary complicationsClinical stage ILung cancer resectionPrimary lung cancerMorbidity of patientsThoracic surgery approachStage lung cancerStandard of careMorbidity of thoracotomyVideo-assisted approachLower mortality rateOverall complicationsPulmonary complicationsThoracotomy groupVATS cohort
2011
An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non–small cell lung cancer
Kim AW, Boffa DJ, Wang Z, Detterbeck FC. An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non–small cell lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2011, 143: 55-63. PMID: 22056364, DOI: 10.1016/j.jtcvs.2011.09.002.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsNeoadjuvant TherapyPneumonectomyTime FactorsConceptsNeoadjuvant therapyPerioperative mortalityRight pneumonectomyLeft pneumonectomyNon-small cell lung cancerCumulative mortalityCell lung cancerSystematic PubMed searchFixed-effects modelPulmonary complicationsLung cancerCommon causePneumonectomyMortality differencesPubMed searchMortality figuresSystematic reviewMortalityTherapyOriginal articlesSearch strategyComplicationsCancerStudyLong-term survival after lung resection for non–small cell lung cancer with circulatory bypass: A systematic review
Muralidaran A, Detterbeck FC, Boffa DJ, Wang Z, Kim AW. Long-term survival after lung resection for non–small cell lung cancer with circulatory bypass: A systematic review. Journal Of Thoracic And Cardiovascular Surgery 2011, 142: 1137-1142. PMID: 21864854, DOI: 10.1016/j.jtcvs.2011.07.042.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLong-term survivalAdvanced non-small cell lung cancerCirculatory bypassLung cancerLung resectionMultivariate analysisSystematic reviewFavorable long-term survivalUnfavorable long-term survivalWorse long-term survivalCox proportional hazards modelUnplanned cardiopulmonary bypassPrimary end pointKaplan-Meier methodCox regression modelProportional hazards modelPerioperative mortalityExtended resectionCardiopulmonary bypassClinical variablesExclusion criteriaResectionHazards model
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2008
Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2008, 3: 37-45. PMID: 18166839, DOI: 10.1097/jto.0b013e31815e5d9a.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCisplatinDeoxycytidineDrug Administration ScheduleFeasibility StudiesFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly-stage non-small cell lung cancerNon-small cell lung cancerCell lung cancerGemcitabine 1000Day 1Neoadjuvant chemotherapyLung cancerResponse ratePathologic complete response rateRandomized phase II trialPhase III settingClinical response rateComplete response ratePerioperative mortality ratePrimary end pointComplete resection ratePhase II trialCarboplatin areaEligible patientsII trialPreoperative regimenResection rateSame regimenUnderwent surgeryMedian survival
2006
Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells
Yim HW, Slebos RJ, Randell SH, Umbach DM, Parsons AM, Rivera MP, Detterbeck FC, Taylor JA. Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells. Cancer Letters 2006, 246: 24-33. PMID: 16517060, DOI: 10.1016/j.canlet.2006.01.023.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBronchiCell Culture TechniquesCell ProliferationCells, CulturedCellular SenescenceChildDNA MethylationEpithelial CellsFemaleHumansLung NeoplasmsMaleMiddle AgedPolymerase Chain ReactionPromoter Regions, GeneticSmokingTelomeraseTime FactorsTumor Cells, CulturedConceptsNormal bronchial epitheliumTelomeric repeat amplification protocolHuman bronchial epithelial cellsBronchial epithelial cellsBronchial epitheliumTelomerase activityLung cancer historyLung cancer statusEpithelial cellsMaximum passage numberTobacco carcinogen exposureHBE cell culturesRepeat amplification protocolExtended culturingHTERT promoterShort-term cultureSmoking historyTobacco smokingPassage numberCancer historyLung carcinogenesisLung carcinomaCancer statusCarcinogen exposureCausative roleInvited commentary
Detterbeck FC. Invited commentary. The Annals Of Thoracic Surgery 2006, 81: 330. PMID: 16368393, DOI: 10.1016/j.athoracsur.2005.08.024.Peer-Reviewed Original Research